MTMaria Rosina Troppmair

Maria Rosina Troppmair

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria Rosina Troppmair has a total of 101 co-authors. Here are the top co-authors by number of shared publications:

  • Heinz Zoller

    Department of Medicine I, Gastroenterology, Hepatology and Endocrinology, Medical University of Innsbruck, Innsbruck, Austria

    4 shared publications
  • Benedikt Schaefer

    Department of Medicine I, Medical University of Innsbruck, Innsbruck, Austria

    3 shared publications
  • Bettina Sarg

    Institute of Medical Biochemistry, Protein Core Facility, Biocenter Medical University of Innsbruck Innsbruck Austria

    2 shared publications
  • Claudia Manzl

    Institute of Neuropathology and Neuromolecular Pathology Medical University of Innsbruck Innsbruck Austria

    2 shared publications
  • Elke Pertler

    Christian Doppler Laboratory for Iron and Phosphate Biology, Department of Internal Medicine I Medical University of Innsbruck Innsbruck Austria

    2 shared publications
  • Herbert Tilg

    Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism, Medizinische Universitat Innsbruck, Innsbruck, Austria

    2 shared publications

Latest Publications

  • Open Access

    Remodelling of Skeletal Muscle During Iron Deficiency Anaemia and Recovery After Intravenous Iron Therapy

    by Elke Pertler, Sonja A. Wagner, Marlene Panzer, Laura Obholzer, Ylena Sonnenburger, Maria R. Troppmair, Martina Saretto, Benedikt Schaefer, Claudia Manzl, Herbert Oberacher, et al.

    Background: The global prevalence of iron deficiency anaemia (IDA) is about 25% and even higher in women of reproductive age and children. IDA can impair skeletal muscle by disrupting oxygen utilization, energy production and contractile function. Haematological effects of intravenous (IV) iron therapy in IDA are well studied, but its impact on muscle and energy metabolism is less clear. We investigated the molecular and functional effects of IDA on skeletal muscle in a mouse model and C2C12 myotubes. The effects of different IV iron formulations on skeletal muscle were compared in iron deficient C2C12 myotubes, in IDA‐mice and patients with IDA. Methods: Treatment effects of the IV iron formulations ferric carboxymaltose (FCM) and ferric derisomaltose (FDI) were studied in IDA mice by tail vein injection of 2‐mg iron. Analyses were carried out 7 days and 4 weeks post‐treatment. C2C12 myotubes were treated with desferrioxamine, followed by incubation with FCM or FDI before mitochondrial respiration, gene expression and metabolite profiles were analysed. Respiratory muscle function was investigated in adults with IDA treated with FCM or FDI as exploratory endpoint in a randomized clinical trial. Results: In our mouse model IDA induced a trend towards impaired skeletal muscle function and a shift to anaerobic metabolism. Only treatment with FDI resulted in a significant increase in muscle type I and type IIb fibre cross‐sectional area when compared to IDA. FDI also induced earlier recovery of contractile protein expression and energy metabolism than FCM. Exploratory proteomic and metabolic analyses revealed that treatment with FDI might restore mitochondrial enzymes and reduce lactate accumulation after 7 days. In vitro, iron‐deficient C2C12 myotubes showed reduced mitochondrial respiration and increased glycolysis with partial recovery by both IV iron formulations. Two weeks after treatment of IDA in adults, FDI caused a significantly better improvement in maximal expiratory pressure than FCM (mean pressure difference between treatments 5.06 cmH 2 O, p = 0.013). This difference appeared unrelated to post‐treatment hypophosphatemia. Conclusions: IDA shows a trend towards impaired skeletal muscle function through metabolic and structural remodelling in mice, which is restored with different kinetics by FDI and FCM. These findings are in accord with exploratory findings from a clinical study indicating better respiratory muscle recovery in FDI‐treated than FCM‐treated IDA patients. Cell culture experiments confirm the effects of IDA on impaired metabolism but did not show differential effects of FCM and FDI. Different tissue pharmacokinetics could explain the distinct in vivo response of both formulations.

  • Open Access

    Liver Transplantation After Immune Checkpoint Inhibition in Hepatocellular Carcinoma—Data From the Multinational LITCHI Registry

    by Ulrike Bauer, Maria R. Troppmair, Najib Ben Khaled, Julia M. Grottenthaler, Friedrich Foerster, Sena Blümel, Sophia Heinrich, Friedrich Sinner, Matthias Pinter, Magdalena Hahn, et al.

    Evidence supporting the safety and efficacy of immune checkpoint inhibitors (ICI) before liver transplantation (LTx) in hepatocellular carcinoma (HCC) is increasing, but risks of graft rejection and tumour recurrence remain major concerns. We evaluated post‐transplant outcomes across 10 European centres using data from the multinational LITCHI ( Li ver t ransplantation after i mmune c heckpoint i nhibition) registry. Clinical and tumour characteristics, ICI regimens and post‐transplant immunosuppression were assessed, and overall and rejection‐free survival were estimated using the log‐rank test. Among 18 patients who underwent LTx following ICI, 15 were treated with atezolizumab plus bevacizumab. One‐year survival was 77% (95% CI 67.3–87.8) and four rejection episodes occurred, with one fatal case after a 13‐day wash‐out and three non‐fatal episodes, each responsive to escalation of immunosuppression. Overall, however, no intensified immunosuppression was required in our cohort. Despite tumour burden beyond Milan criteria in most patients before ICI initiation, HCC recurrence occurred in only one patient.


  • Top Cited Papers
    Open Access

    Ferric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with Iron Deficiency Anemia

    by Sonja Astrid Wagner, Marlene Panzer, Elke Pertler, Stefan Redl, Martina Saretto, Benedikt Schaefer, Lorenz Michael Pammer, Laura Obholzer, Maria Rosina Troppmair, Michael W Hess, et al.

    Modern intravenous (IV) iron formulations allow treatment of iron deficiency anemia (IDA) with one or two infusions. Ferric carboxymaltose (FCM) is a widely used IV iron, which causes hypophosphatemia in the majority of patients. Osteomalacia and fractures are increasingly recognized after repeated infusions of FCM. It is unknown why ferric derisomaltose (FDI) rarely causes hypophosphatemia. In this study, we compare the effects of FCM and FDI on fracture risk and investigate potential underlying mechanisms explaining different effects on bone- and mineral-metabolism. For this aim, fracture rate and osteomalacia were assessed in a cohort of 357 patients treated with either drug, which reported a significantly higher rate of incident osteomalacia or fracture after FCM. These findings were validated in over 20,000 patients from the TriNetX database, where FCM-treatment was independently associated with a higher fracture risk compared with FDI. The underlying mechanisms were investigated in a mouse model of IDA treated with FCM or FDI, an osteocyte model and biochemically. FCM caused lower expression of collagen and ossification genes, associated with significantly higher bone iron concentrations than FDI. Electron microscopy showed iron-loaded vesicles in osteoblasts and early osteocytes. FCM but not FDI inhibited binding of dentin matrix protein 1 to [alpha]V[beta]3-integrin on osteocytes. This is a potential mechanism for reduced bone formation and higher levels of intact fibroblast-growth factor-23 after FCM. Our data report that IDA and FCM treatment can directly impair bone formation and increase fracture risk.


  • Open Access

    Characterization of ferroportin disease and SLC40A1-related hemochromatosis – Results from the EASL non-HFE registry

    by Maria Rosina Troppmair, Andrea Ricci, Stefania Scarlini, Sara Pelucchi, Graça Porto, Fabiana Busti, Mayka Sanchez, Hansi Weissensteiner, Sebastian Schönherr, Lukas Forer, et al.


  • Open Access

    Tetrahydrobiopterin enhances regulatory T- and mast cell proliferation and alters cytokines expression in a murine heart transplant model

    by Susanne Ebner, Bernhard Texler, Florian Nardin, Maria R. Troppmair, Anh Vu Nguyen, Benno Cardini, Jakob Troppmair, Georg Schäfer, Gudrun C. Thalhammer-Thurner, Kerstin Nirtl, et al.

    Administration of tetrahydrobiopterin (BH4) has been shown to attenuate acute allograft rejection in a murine heart transplantation model in a manner similar to that of cyclosporine A. However, its mechanism of action on immune cells remains largely unknown. A fully MHC-mismatched (C3H/He to C57BL/6) mouse heart transplant model was used in this study. The recipients were treated with BH4 or cyclosporine A six days. The degree of acute rejection was assessed by histopathological analysis, splenocytes were analyzed by flow cytometry, and cytokine production was estimated based on the level of protein and RNA in sera and grafts and in vitro in T cell cultures. Proliferation of regulatory T cells and mast cells, suppressor capacity of Tregs, and MLR of T cells were conducted in vitro. Survival curves confirmed the significant improvement observed in the BH4-treated animals. BH4-treatment resulted in a substantial increase in Tregs and mast cells in the secondary lymphoid organs. In vitro assays showed increased proliferation of BH4-treated Tregs and mast cells. Cytokine production in vivo and in vitro in BH4-treated animals revealed an increase in the expression of IL-10, IL-5 and IL-4. BH4-dependent mast cell-derived tryptophan hydroxylase-1 could be excluded as a treatment target in recipient knockout mice. These data suggest that BH4 modulates the innate and adaptive immune systems, resulting in increased proliferation of regulatory T and mast cells accompanied by a modulation of anti-inflammatory cytokines.